Role of NADPH oxidase in the endothelial dysfunction and oxidative stress in aorta of aged spontaneous hypertensive rats

Iranian Journal of Basic Medical Sciences

Volumn 13, Issue 2 SPRING, 2010, Pages 48-56

  Taye, Ashraf ^a   Wind, Sven ^b  

^a Minia University   (Egypt)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Aorta; Endothelial dysfunction; Oxidative stress; Spontaneously hypertensive rats

Indexed keywords

ACETYLCHOLINE; APOCYNIN; ISOENZYME; N(G) NITROARGININE METHYL ESTER; OXIDOREDUCTASE INHIBITOR; OXIPURINOL; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; UNCLASSIFIED DRUG; VAS 2870;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL REACTIVITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SYNTHESIS; HYPERTENSION; IN VITRO STUDY; MALE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; STRAIN DIFFERENCE; UPREGULATION; VASODILATATION; WISTAR KYOTO RAT;

RATTUS;

EID: 77952749673     PISSN: 20083866     EISSN: 20083874     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: The role of oxidant stress. Circ Res 2000; 87:840-844.
2. Potenza MA, Gagliardi S, Nacci C, Carratu MR, Montagnani M. Endothelial dysfunction in diabetes: From mechanisms to therapeutic targets. Curr Med Chem 2009; 16:94-112.
3. Higashi Y, Sasaki S, Nakagawa K, Matsuura H, Oshima T, Chayama K. Endothelial function and oxidative stress in renovascular hypertension. N Engl J Med 2002; 346:1954-1962.
4. Redon J, Oliva MR, Tormos C, Giner V, Chaves J, Iradi A, Saez GT. Antioxidant activities and oxidative stress byproducts in human hypertension. Hypertension 2003; 41:1096-1101 (Pubitemid 36548609)
5. Harrison DG, Gongora MC. Oxidative stress and hypertension. Med Clin North Am 2009; 93:621-635.
6. Landmesser U, Cai H, Dikalov S, McCann L, Hwang J, Jo H, Holland SM, Harrison DG. Role of p47(phox) in vascular oxidative stress and hypertension caused by angiotensin ll. Hypertension 2002; 40:511-515.
7. Nishiyama A, Yao L, Nagai Y, Miyata K, Yoshizumi M, Kagami S, et al. Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats. Hypertension 2004; 43:841-848. (Pubitemid 38405598)
8. Tanito M, Nakamura H, Kwon YW, Teratani A, Masutani H, Shioji K, et al. Enhanced oxidative stress and impaired thioredoxin expression in spontaneously hypertensive rats. Antioxid Redox Signal 2004; 6:89-97. (Pubitemid 38063979)
9. Hamilton CA, Brosnan MJ, McIntyre M, Graham D, Dominiczak AF. Superoxide excess in hypertension and aging: A common cause of endothelial dysfunction. Hypertension 2001; 37:529-534. (Pubitemid 32199023)
10. Zalba G, Beaumont FJ, San Jose G, Fortuno A, Fortuno MA, Etayo JC, et al. Vascular NADH/NADPH oxidase is involved in enhanced superoxide production in spontaneously hypertensive rats. Hypertension 2000; 35:1055-1061. (Pubitemid 30327257)
11. Griendling KK, Sorescu D, Ushio-Fukai M. NADPH oxidase: Role in cardiovascular biology and disease. Circ Res 2000; 86:494-501. (Pubitemid 30165039)
12. Gao L, Mann GE. Vascular nad(p)h oxidase activation in diabetes: A double-edged sword in redox signalling. Cardiovasc Res 2009; 82:9-20.
13. Collins-Underwood JR, Zhao W, Sharpe JG, Robbins ME. NADPH oxidase mediates radiation-induced oxidative stress in rat brain microvascular endothelial cells. Free Radic Biol Med 2008; 45:929-938.
14. Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 2003; 111:1201-1209. (Pubitemid 36519937)
15. Nakazono K, Watanabe N, Matsuno K, Sasaki J, Sato T, Inoue M. Does superoxide underlie the pathogenesis of hypertension? Proc Natl Acad Sci USA 1991; 88:10045-10048.
16. Wallwork CJ, Parks DA, Schmid-Schonbein GW. Xanthine oxidase activity in the dexamethasone-induced hypertensive rat. Microvasc Res 2003; 66:30-37. (Pubitemid 36765442)
17. Park JB, Touyz RM, Chen X, Schiffrin EL. Chronic treatment with a superoxide dismutase mimetic prevents vascular remodeling and progression of hypertension in salt-loaded stroke-prone spontaneously hypertensive rats. Am J Hypertens 2002; 15:78-84. (Pubitemid 34102277)
18. Paravicini TM, Chrissobolis S, Drummond GR, Sobey CG. Increased NADPH-oxidase activity and NOX4 expression during chronic hypertension is associated with enhanced cerebral vasodilatation to nadph in vivo. Stroke 2004; 35:584-589. (Pubitemid 38174454)
19. Hamilton CA, Brosnan MJ, Al-Benna S, Berg G, Dominiczak AF. NADPH oxidase inhibition improves endothelial function in rat and human blood vessels. Hypertension 2002; 40:755-762. (Pubitemid 35278615)
20. Lassegue B, Sorescu D, Szocs K, Yin Q, Akers M, Zhang Y, et al. Novel gp91(phox) homologues in vascular smooth muscle cells : NOX1 mediates angiotensin ii-induced superoxide formation and redox-sensitive signaling pathways. Circ Res 2001; 88:888-894. (Pubitemid 32441466)
21. 4 by the renin-angiotensin system in vitro and in vivo. Free Radic Biol Med 2001; 31:1456-1464.
22. Cai H, Griendling KK, Harrison DG. The vascular NADPH oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol Sci 2003; 24:471-478.
23. Cifuentes ME, Pagano PJ. Targeting reactive oxygen species in hypertension. Curr Opin Nephrol Hypertens 2006; 15:179-186.
24. Zhao H, Kalivendi S, Zhang H, Joseph J, Nithipatikom K, Vasquez-Vivar J, et al. Superoxide reacts with hydroethidine but forms a fluorescent product that is distinctly different from ethidium: Potential implications in intracellular fluorescence detection of superoxide. Free Radic Biol Med 2003; 34:1359-1368.
25. Munzel T, Afanas'ev IB, Kleschyov AL, Harrison DG. Detection of superoxide in vascular tissue. Arterioscler Thromb Vasc Biol 2002; 22:1761-1768.
26. Yatabe J, Sanada H, Yatabe MS, Hashimoto S, Yoneda M, Felder RA, et al. Angiotensin ii type 1 receptor blocker attenuates the activation of ERK and NADPH oxidase by mechanical strain in mesangial cells in the absence of angiotensin ii. Am J Physiol Renal Physiol 2009; 296:F1052-1060.
27. Liu F, Wei CC, Wu SJ, Chenier I, Zhang SL, Filep JG, et al. Apocynin attenuates tubular apoptosis and tubulointerstitial fibrosis in transgenic mice independent of hypertension. Kidney Int 2009; 75:156-166.
28. Jiang F, Drummond GR, Dusting GJ. Suppression of oxidative stress in the endothelium and vascular wall. Endothelium 2004; 11:79-88.
29. Ambasta RK, Kumar P, Griendling KK, Schmidt HH, Busse R, Brandes RP. Direct interaction of the novel nox proteins with p22phox is required for the formation of a functionally active nadph oxidase. J Biol Chem 2004; 279:45935-45941.
30. Li H, Witte K, August M, Brausch I, Godtel-Armbrust U, Habermeier A, et al. Reversal of endothelial nitric oxide synthase uncoupling and up-regulation of endothelial nitric oxide synthase expression lowers blood pressure in hypertensive rats. J Am Coll Cardiol 2006; 47: 2536-2544
31. Cifuentes ME, Rey FE, Carretero OA, Pagano PJ. Upregulation of p67 (phox) and gp91 (phox) in aortas from angiotensin ii-infused mice. Am J Physiol Heart Circ Physiol 2000; 9:H2234-2240.
32. Mollnau H, Wendt M, Szocs K, Lassegue B, Schulz E, Oelze M, et al. Effects of angiotensin ii infusion on the expression and function of nad(p)h oxidase and components of nitric oxide/cgmp signaling. Circ Res 2002; 90:E58-65.
33. Ago T, Kitazono T, Ooboshi H, Iyama T, Han YH, Takada J, et al. Nox4 as the major catalytic component of an endothelial nad(p)h oxidase. Circulation 2004; 109:227-233.
34. Wang HD, Xu S, Johns DG, Du Y, Quinn MT, Cayatte AJ, et al. Role of NADPH oxidase in the vascular hypertrophic and oxidative stress response to angiotensin ii in mice. Circ Res 2001; 88:947-953.
35. Touyz RM, Mercure C, He Y, Javeshghani D, Yao G, Callera GE, et al. Angiotensin ii-dependent chronic hypertension and cardiac hypertrophy are unaffected by gp91phox-containing NADPH oxidase. Hypertension 2005; 45:530-537.
36. Dikalova A, Clempus R, Lassegue B, Cheng G, McCoy J, Dikalov S, et al. NOX1 overexpression potentiates angiotensin ii-induced hypertension and vascular smooth muscle hypertrophy in transgenic mice. Circulation 2005; 112:2668-2676. (Pubitemid 41532604)
37. Matsuno K, Yamada H, Iwata K, Jin D, Katsuyama M, Matsuki M, et al. Nox1 is involved in angiotensin iimediated hypertension: A study in nox1-deficient mice. Circulation 2005; 112:2677-2685. (Pubitemid 41532605)
38. Wassmann S, Laufs U, Muller K, Konkol C, Ahlbory K, Baumer AT, et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 2002; 22:300-305. (Pubitemid 34127043)
39. Stolk J, Hiltermann TJ, Dijkman JH, Verhoeven AJ. Characteristics of the inhibition of nadph oxidase activation in neutrophils by apocynin, a methoxy-substituted catechol. Am J Respir 1994; 11:95-102.
40. Pechanova O, Jendekova L, Vrankova S. Effect of chronic apocynin treatment on nitric oxide and reactive oxygen species production in borderline and spontaneous hypertension. Pharmacol Rep. 2009; 61:116-122.
41. Vejrazka M, Micek R, Stipek S. Apocynin inhibits NADPH oxidase in phagocytes but stimulates ros production in non-phagocytic cells. Biochim Biophys Acta 2005; 1722:143-147. (Pubitemid 40299004)
42. Riganti C, Costamagna C, Bosia A, Ghigo D. The nadph oxidase inhibitor apocynin (acetovanillone) induces oxidative stress. Toxicol Appl Pharmacol 2006; 212:179-187
43. Tegtmeier F, Schinzel R, Wingler K, Scheurer P, Schmidt HH. Compounds containing a n-heteroaryl moiety linked to fused ring moieties for the inhibition of NADPH oxidases and platelet activation. European Patent Application 2005; 598 354 A1.
44. Ten Freyhaus H, Huntgeburth M, Wingler K, Schnitker J, Baumer AT, Vantler M, Bekhite MM, Wartenberg M, Sauer H, Rosenkranz S. Novel NOX inhibitor VAS2870 attenuates pdgf-dependent smooth muscle cell chemotaxis, but not proliferation. Cardiovasc Res 2006; 71:331-341.
45. Stielow C, Catar RA, Muller G, Wingler K, Scheurer P, Schmidt HH, Morawietz H. Novel NOX inhibitor of oxldl-induced reactive oxygen species formation in human endothelial cells. Biochem Biophys Res Commun 2006; 344:200-205.